Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N.

Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.

2.

Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.

Ysebaert L, Laprévotte E, Klein C, Quillet-Mary A.

Blood Cancer J. 2015 Nov 13;5:e367. doi: 10.1038/bcj.2015.93. No abstract available.

3.

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.

Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J, Bensussan A, Giustiniani J.

Sci Rep. 2015 Jul 8;5:11874. doi: 10.1038/srep11874.

4.

Plasticity of γδ T Cells: Impact on the Anti-Tumor Response.

Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, Bonnefoy N.

Front Immunol. 2014 Dec 8;5:622. doi: 10.3389/fimmu.2014.00622. eCollection 2014. Review.

5.

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.

6.

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.

Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A, Bastid J.

Sci Rep. 2013 Dec 9;3:3456. doi: 10.1038/srep03456.

7.

Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.

Laprevotte E, Voisin G, Ysebaert L, Klein C, Daugrois C, Laurent G, Fournie JJ, Quillet-Mary A.

J Immunol. 2013 Oct 1;191(7):3634-40. doi: 10.4049/jimmunol.1300187. Epub 2013 Aug 30.

8.

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.

Laprevotte E, Ysebaert L, Klein C, Valleron W, Blanc A, Gross E, Laurent G, Fournié JJ, Quillet-Mary A.

Leuk Res. 2013 Apr;37(4):440-6. doi: 10.1016/j.leukres.2012.11.015. Epub 2012 Dec 20.

PMID:
23259986
9.

Specific small nucleolar RNA expression profiles in acute leukemia.

Valleron W, Laprevotte E, Gautier EF, Quelen C, Demur C, Delabesse E, Agirre X, Prósper F, Kiss T, Brousset P.

Leukemia. 2012 Sep;26(9):2052-60. doi: 10.1038/leu.2012.111. Epub 2012 Apr 23.

PMID:
22522792
10.

Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.

Capietto AH, Keirallah S, Gross E, Dauguet N, Laprévotte E, Jean C, Gertner-Dardenne J, Bezombes C, Quillet-Mary A, Poupot M, Ysebaert L, Laurent G, Fournié JJ.

Curr Drug Targets. 2010 Jul;11(7):790-800. Review.

PMID:
20370648

Supplemental Content

Loading ...
Support Center